Summary of findings 2. Erythromycin compared to no treatment for guttate psoriasis.

Erythromycin compared to no treatment for guttate psoriasis
Patient or population: guttate psoriasis Setting: inpatients in department of dermatology Intervention: erythromycin Comparison: no treatment
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with no treatment	Risk with erythromycin
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1	‐	‐	‐	‐	‐	Not measured
Proportion of participants with adverse events and severe adverse events	‐	‐	‐	‐	‐	Not measured
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1)	‐	‐	‐	‐	‐	Not measured
Proportion of participants achieving PASI 75 or PGA 1 to 2	‐	‐	‐	‐	‐	Not measured Results were only reported as mean PASI at baseline and at 6 weeks. No difference was found between groups for mean PASI at 6 weeks.
Risk of having at least one relapse at long‐term follow‐up	‐	‐	‐	‐	‐	Not measured
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence High quality/certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality/certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality/certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality/certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect